I hereby certify that this correspondence is being electronically filed in the United States Patent and

Trademark Office on May 22, 2009.

Patent Application Docket No. C.R.107 Serial No. 10/539,847

Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Chih Min Kam

Art Unit

1656

Applicants

Richard Joseph Fagan, Christopher Benjamin Phelps, Christine Power,

Richard James Mitter, Ursula Boschert, Yolande Chvatchko

Serial No.

10/539,847

Filed

June 20, 2005

Metalloprotease Proteins

Conf. No.

5016

For

Commissioner for Patents

:

P.O. Box 1450

Alexandria, VA 22313

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS

Sir:

The Notice to File Corrected Application Papers mailed April 8, 2009 indicates that replacement drawings in compliance with 37 CFR 1.84 and 37 CFR 1.21(d) are required in the above-referenced patent application. Specifically, Figures 10 and 13 are not acceptable because they are continued over several pages without proper labeling.

Transmitted herewith are replacement pages 11/18 (continuation of Figure 10) and 15/18 (continuation of Figure 13). In addition, Applicants have submitted replacement page 5/18 (Figure 5) because the consensus polyadenylation site was in red and was illegible. The consensus polyadenylation site is now underlined. Replacement page 14/18 (Figure 13) has also been replaced to underline the active sites which were previously highlighted.

I hereby certify that the paper copy as filed and the replacement drawing sheet contain the same information and that no new material is added or deleted by this submission.

The Commissioner is hereby authorized to charge any additional fees which may be required to Deposit Account No. 19-0065.

Respectfully submitted,

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100 Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

FCE/sl

Attachments: Replacement pages 5/18 (Figure 5), 11/18 (Figure 10 continuation), 14/18 (Figure 13) and 15/18 (Figure 13 continuation).